What Researchers Did
Researchers conducted a retrospective study to compare the effectiveness of different hyperbaric oxygen therapy doses (HBO18 vs. HBO10) for acute central retinal artery occlusion.
What They Found
They found that the HBO18 group showed significantly greater improvement in ΔBCVA (median 0.62 LogMAR) compared to the HBO10 group (median 0.22 LogMAR, p < 0.001). Multivariate analysis indicated HBO18 use was associated with a 0.5 LogMAR improvement in BCVA at 24 hours, with no severe adverse events reported.
What This Means for Canadian Patients
Canadian patients experiencing acute central retinal artery occlusion might benefit more from an initial hyperbaric oxygen therapy dose of 2.8 ATA (HBO18) compared to 2.0 ATA (HBO10). This could lead to better short-term vision improvement, suggesting a potentially more effective treatment approach.
Canadian Relevance
This study has no direct Canadian connection as indicated by the metadata.
Study Limitations
A limitation of this study is its retrospective design, which may be subject to confounding factors and selection bias.